Cargando…

Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer

Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiographic syndrome with seizures, headache, altered mental status and visual disturbances. It is typically associated with posterior cerebral white matter oedema on neuroimaging. There is an increasing number of cases of PRES repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abughanimeh, Omar K, Qasrawi, Ayman H, Tahboub, Mohammad Y, Abu Ghanimeh, Mouhanna K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Institute of Radiology 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159153/ https://www.ncbi.nlm.nih.gov/pubmed/30363210 http://dx.doi.org/10.1259/bjrcr.20170033

Ejemplares similares

Trastuzumab-associated Posterior Reversible Encephalopathy Syndrome
por: Abughanimeh, Omar, et al.
Publicado: (2018)

Hemophagocytic Lymphohistiocytosis Complicating Systemic Sarcoidosis
por: Abughanimeh, Omar, et al.
Publicado: (2018)

Achalasia after bariatric Roux-en-Y gastric bypass surgery reversal
por: Abu Ghanimeh, Mouhanna, et al.
Publicado: (2017)

Hereditary Thrombophilia Testing Among Hospitalized Patients: Is It Warranted?
por: Abughanimeh, Omar K, et al.
Publicado: (2022)

Metastatic Lung Adenocarcinoma Presenting with Hypereosinophilia
por: Abughanimeh, Omar, et al.
Publicado: (2018)

A Case of Multiple Myeloma Associated with Extramedullary Plasmacytoma of the Gallbladder Manifesting as Acute Cholecystitis
por: Abughanimeh, Omar, et al.
Publicado: (2018)

Pylephlebitis Caused by Actinomyces Bacteremia
por: Abughanimeh, Omar, et al.
Publicado: (2018)

BRAF V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis
por: Qasrawi, Ayman, et al.
Publicado: (2017)

Gastric Metastasis from Renal Cell Carcinoma, Clear Cell Type, Presenting with Gastrointestinal Bleeding
por: Abu Ghanimeh, Mouhanna, et al.
Publicado: (2017)

Intrahepatic Cholangiocarcinoma Masquerading as Acute Fatty Liver of Pregnancy: A Case Report and Review of the Literature
por: Qasrawi, Ayman, et al.
Publicado: (2018)

Gastric Metastases from Lung Adenocarcinoma Causing Gastrointestinal Bleeding
por: Qasrawi, Ayman, et al.
Publicado: (2017)

Colopancreatic Fistula: An Uncommon Complication of Recurrent Acute Pancreatitis
por: Abu Ghanimeh, Mouhanna, et al.
Publicado: (2018)

Dental Impaction in the Cecum: Case Report and Review of Gastrointestinal Foreign Body Impactions
por: Abu Ghanimeh, Mouhanna, et al.
Publicado: (2018)

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
por: Fischel, J-L, et al.
Publicado: (2001)

Venous thromboembolism prophylaxis in inflammatory bowel disease flare-ups
por: Kaddourah, Osama, et al.
Publicado: (2019)

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
por: Souglakos, J, et al.
Publicado: (2006)

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pancreatic Adenocarcinoma
por: Dacie, Ruth, et al.
Publicado: (2020)

Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2002)

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
por: Garufi, C, et al.
Publicado: (2003)

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
por: Barone, C, et al.
Publicado: (2007)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
por: Teufel, Andreas, et al.
Publicado: (2004)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
por: Chun, Jung Won, et al.
Publicado: (2022)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
por: Verbruggen, Lise, et al.
Publicado: (2023)

FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
por: Zhang, Xiaowei, et al.
Publicado: (2022)

5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
por: Kerr, D. J.
Publicado: (1989)

Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
por: Kuehr, Thomas, et al.
Publicado: (2004)

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Park, Se Jun, et al.
Publicado: (2021)

Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin
por: Gonzalez, M A, et al.
Publicado: (2003)

Fluorouracil/folinic acid/oxaliplatin: Various toxicities: 2 case reports
Publicado: (2021)

Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen
por: Dedić Plavetić, Natalija, et al.
Publicado: (2014)

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
por: Raoul, Jean-Luc, et al.
Publicado: (2009)

Durable complete response in a patient with metastatic left‐sided colon cancer treated with 5‐fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report
por: Kim, Esther, et al.
Publicado: (2019)

Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study
por: Miki, Masami, et al.
Publicado: (2022)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
por: Souglakos, J, et al.
Publicado: (2012)

5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.
por: Jebb, S. A., et al.
Publicado: (1994)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o6b8klb1mf25k2n2o742i1gdok